The drug label now notes that increases in cholesterol have occurred with treatment and triglyceride and cholesterol testing should be performed prior to initiating and at periodic intervals during therapy.
The drug is limited to patients who have failed other therapies because of serious safety concerns including elevated liver enzymes, elevated LDL cholesterol, hypertension, and gastrointestinal perforations. ... cholesterol-lowering medications.
What gets lost in all of the superficial coverage of "Fat state vs. ... Not-as-fat state" is how obesity is measured. In health care we use the BMI, or body mass index, as the determinant.
Some, like Fat Doctor and Ob/Gyn Kenobi, have separate, well-established blogs of their own. ... You have such an obligation to your patients,” said Fat Doctor, a hospitalist, in a phone interview.
It is the first in a new class, PCSK9 inhibitors. In trials of 2,476 participants, those taking the drug had an average reduction in LDL cholesterol ranging from 36% to
His blood pressure is 142/85 mm Hg. His LDL cholesterol is 140 mg/dL (3.62 mmol/L) and his HDL cholesterol is 30 mg/dL (0.78 mmol/L).
That is not meaningful and additionally the drug is not completely safe,” said David Gortler, PharmD, a former medical officer on the FDA's lipids and obesity team and current associate ... Researchers set out to determine whether a diet that reduced
Weight loss miracle? Americans are fat. That's fact, not judgment. The reasons for our obesity are complex, without simple answers. ... Some have hypothesized that it may have a role in fat metabolism and potential as an aid to weight loss.
We have another saying that wheat is making us fat, yet another contending that grains are making us stupid. ... We could have been right about reducing saturated fat intake, and wrong about what we ate instead.
A warning about the potential for increased risk of muscle injury from the cholesterol-lowering medication simvastatin (Zocor) 80 mg. ... The FDA also announced plans to review the primary data from the ACCORD Lipid Trial, which evaluated the potential